Vaccines as Epidemic Insurance
AbstractThis paper explores the relationship between the research for and development of vaccines against global pandemics and insurance. It shows that development in advance of pandemics of a portfolio of effective and government-approved vaccines does have some insurance properties: it requires incurring costs that are certain (the costs of discovering, developing, and testing vaccines) in return for protection against large losses (if a pandemic treatable with one of the vaccines occurs) but also with the possibility of no benefit (from a vaccine against a disease that never reaches the pandemic stage). It then argues that insurance against the latter event might usefully be offered to organizations developing vaccines, and explores the benefits of insurance payments to or on behalf of countries who suffer from unpredictable pandemics. These ideas are then related to recent government, industry, and philanthropic efforts to develop better policies to make vaccines against pandemics available on a timely basis. View Full-Text
Share & Cite This Article
Pauly, M.V. Vaccines as Epidemic Insurance. Int. J. Environ. Res. Public Health 2017, 14, 1304.
Pauly MV. Vaccines as Epidemic Insurance. International Journal of Environmental Research and Public Health. 2017; 14(11):1304.Chicago/Turabian Style
Pauly, Mark V. 2017. "Vaccines as Epidemic Insurance." Int. J. Environ. Res. Public Health 14, no. 11: 1304.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.